durvalumab,paclitaxel,carboplatin,cisplatin,gemcitabine,pemetrexed
astrazeneca
['aegean']
the aegean phase iii clinical trial found a 32% lower chance of disease recurrence, progression or death with immunotherapy plus chemotherapy versus chemotherapy alone. learn more about the results that heymach shared at #aacr23: #endcancer 2/2
MD Anderson is a global leader in cancer care, research, education and training, and prevention. Appointments available: 1-877-632-6789